The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ZMC1 helped coordinate zinc ions at appropriate sites to restore the structure and function of the R175 mutant442 and significantly inhibited tumor growth in mice carrying the R175H mutation.441”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [442]
In the citing paper
“ZMCI treatment increased the folded R175 mutant protein by twofold.442”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [442]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551 · cited 1×
“Structural studies of WT p53 have shown that p53 requires a single zinc ion (coordinated by four amino acids C176, H179 on the L2 loop, and C238, and C242 on the L3 loop) for proper folding [10, 11].”
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 1×
“Restoration of p53 function in mouse tumor models has been shown to be highly therapeutic, thus reactivating mutant p53 pharmacologically has been a highly sought after goal in anti-cancer drug development [5-7].”
Acetylation of the p53 DNA-binding domain regulates apoptosis induction.
Sykes, S. M., Mellert, H. S., Holbert, M. A., Li, K., Marmorstein, R., Lane, W. S., & McMahon, S. B. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.11.026 · Cited by 752
Modeling the Therapeutic Efficacy of p53 Restoration in Tumors
Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600 · cited 1×
“Restoration of p53 function in mouse tumor models has been shown to be highly therapeutic, thus reactivating mutant p53 pharmacologically has been a highly sought after goal in anti-cancer drug development [5-7].”
Research works printed but not linked: 21
- Ley, 2013, Mutational landscape and significance across 12 major cancer types, Nature, 502, 333, 10.1038/nature12634 · DOI · Paper page
- Epstein, 1995, The spectrum of mutations at the p53 locus. Evidence for tissue-specific mutagenesis, selection of mutant alleles, and a “gain of function” phenotype, Ann N Y Acad Sci, 768, 111, 10.1111/j.1749-6632.1995.tb12115.x · DOI
- Moll, 2011, Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells, Mol Cancer Res, 9, 577, 10.1158/1541-7786.MCR-10-0534 · DOI · Paper page
- Carpizo, 2012, Allele-specific p53 mutant reactivation, Cancer Cell, 21, 614, 10.1016/j.ccr.2012.03.042 · DOI · Paper page
- Richardson, 2009, Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors, J Med Chem, 52, 5271, 10.1021/jm900552r · DOI · Paper page
- Loh, 2003, Structure, function, and aggregation of the zinc-free form of the p53 DNA binding domain, Biochemistry, 42, 2396, 10.1021/bi026635n · DOI · Paper page
- Milner, 1993, A structural role for metal ions in the “wild-type” conformation of the tumor suppressor protein p53, Cancer Res, 53, 1739
- Hainaut, 2000, Metalloregulation of the tumor suppressor protein p53: zinc mediates the renaturation of p53 after exposure to metal chelatorsand in intact cells, Oncogene, 19, 5227, 10.1038/sj.onc.1203907 · DOI · Paper page
- Loh, 2010, The missing zinc: p53 misfolding and cancer, Metallomics, 2, 442, 10.1039/c003915b · DOI
- Loh, 2007, Zn(2+)-dependent misfolding of the p53 DNA binding domain, Biochemistry, 46, 2630, 10.1021/bi062106y · DOI
- Fersht, 2007, Structure-function-rescue: the diverse nature of common p53 cancer mutants, Oncogene, 26, 2226, 10.1038/sj.onc.1210291 · DOI · Paper page
- Maret, 2010, Cytosolic zinc buffering and muffling: their role in intracellular zinc homeostasis, Metallomics, 2, 306, 10.1039/b926662c · DOI · Paper page
- Luecke, 2007, Structure of the human p53 core domain in the absence of DNA, Acta Crystallogr D Biol Crystallogr, 63, 276
- Anderson, 2009, Posttranslational modification of p53: cooperative integrators of function, Cold Spring Harb Perspect Biol, 1, a000950
- Milner, 1993, Redox modulation of p53 conformation and sequence-specific DNA binding, Cancer Res, 53, 4469
- Lowe, 2012, The relationship between zinc intake and serum/plasma zinc concentration in children: a systematic review and dose-response meta-analysis, Nutrients, 4, 841, 10.3390/nu4080841 · DOI
- Chumakov, 2005, The antioxidant function of the p53 tumor suppressor, Nat Med, 11, 1306, 10.1038/nm1320 · DOI · Paper page
- D'Orazi, 2011, Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs, Cell Cycle, 10, 1679, 10.4161/cc.10.10.15642 · DOI
- D'Orazi, 2013, A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells, J Exp Clin Cancer Res, 32, 72, 10.1186/1756-9966-32-72 · DOI
- Prives, 2012, Mutant p53: one name, many proteins, Genes Dev, 26, 1268, 10.1101/gad.190678.112 · DOI · Paper page
- Fersht, 2000, Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy, Oncogene, 19, 1245, 10.1038/sj.onc.1203434 · DOI · Paper page
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Targeting mutant p53 for efficient cancer therapy
Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.109 · Cited by 889
Soussi, T., & Wiman, K. G. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2015.53 · Cited by 305
Bykov, V. J. N., Zhang, Q., Zhang, M., Ceder, S., Abrahmsen, L., & Wiman, K. G. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00021 · Cited by 137
Targeting Therapies for the p53 Protein in Cancer Treatments
Levine, A. J. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055455 · Cited by 84
Metadata
- Authors
- Yu, X., Blanden, A. R., Narayanan, S., Jayakumar, L., Lubin, D., Augeri, D., David Kimball, S., Loh, S. N., & Carpizo, D. R.
- Affiliations
- Rutgers Cancer Institute of New Jersey, New Jersey
- Department of Biochemistry and Molecular Biology, SUNY Upstate Medical University, Syracuse, New York
- Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey
- Department of Medicinal Chemistry, Rutgers Ernest Mario School of Pharmacy, Piscataway, New Jersey
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2014-09-03
- Volume
- 5
- Issue
- 19
- Pages
- 8879-8892
- ISSN
- 1949-2553
- Cited by
- 102
- References
- 6
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
